Julia Feygin, Director of Global Scientific Partnerships at AstraZeneca, shared a post on LinkedIn:
“Thrilled to share that I’ve been appointed to a new role at AstraZeneca as Director of Global Scientific Partnerships within the Oncology Medical Affairs organization. My focus will be to help bring the promise of great science and innovation to patients everywhere – through collaborative partnerships and co-created, pragmatic strategies that tackle systemic barriers, accelerate practice-relevant evidence generation, and expand patient access to early detection, precision diagnostics, clinical trials, and guideline-concordant care.
AstraZeneca’s bold ambition to eliminate cancer as a cause of death is an incredibly inspiring North Star, and health equity is at its core because ambition must be matched by reach. If innovation does not reach patients, its promise goes unmet.
Around 20 million new cancer cases are diagnosed globally each year, but only a small fraction of these patients receive care in major centers. The vast majority are treated in local community care settings, and in many cases, without equitable access to cutting-edge treatments or clinical trials (which often represent the earliest access to innovation).
Our goal is to turn discovery and innovation into scalable patient impact by closing care gaps between centers of excellence and community oncology care settings – to help bring high-quality care and trial opportunities closer to home and accessible to all patients, regardless of their location or socioeconomic status.
The mission is deeply personal to me – as it is for so many of us. Every day, I remember the childhood promise I made to my dad before he lost his battle to pancreatic cancer – that when I grow up, I will help make sure that stories like ours have a different ending for others.
I’m so proud to continue honoring this promise at a company that rapidly and rigorously advances the boundaries of science while bringing forward bold initiatives that transcend brands and products to partner across the global cancer ecosystem and address the system-level changes that are needed to truly transform the landscape of oncology care for patients and their loved ones around the world.”